Let’s partner to transform medicine—
and succeed together
At Assembly Bio, we take pride in the ingenuity, agility and rigor we apply to the scientific research we do. As a result, we’ve built some of the most cutting-edge drug discovery platforms in biopharma today. Our R&D effort is strong. It can be even stronger with the right academic and corporate partnerships in place.
Assembly Bio and Gilead have entered into a long-term partnership and collaboration to research and develop next-generation therapies. Under the collaboration, Gilead may exercise its option rights to exclusively license Assembly Bio programs and would control research, development and commercialization of programs it opts into while Assembly Bio may elect to certain profit/cost share and co-promotion options in the US for such Gilead-optioned programs.
Gilead has exercised its option to exclusively license Assembly Bio’s HSV helicase-primase inhibitor program for recurrent genital herpes.
If your organization is interested in collaborating with Assembly Bio
on a potential research and development venture, please
contact us at: BD@assemblybio.com.